Table 2 Summary of findings (SoF) table using GRADE methodology
LMWH compared to VKA for patients with cancer requiring long term anticoagulation for VTE | ||||||
|---|---|---|---|---|---|---|
Patient or population: patients with cancer requiring long term anticoagulation for VTE Settings: Outpatient Intervention: LMWH Comparison: VKA | ||||||
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
Assumed risk | Corresponding risk | |||||
VKA | LMWH | |||||
Mortality (follow-up: 3–6 months) | Population | RR 0.95 (0.81 to 1.11) | 1346 (4) | ⊕⊕OO low1,2 | ||
310 per 1000 | 294 per 1000 (251 to 344) | |||||
Low risk population | ||||||
30 per 1000 | 28 per 1000 (24 to 33) | |||||
High risk population | ||||||
1000 per 1000 | 950 per 1000 (810 to 1110) | |||||
Recurrent VTE (binary) (follow-up: 3–12 months) | Population | RR 0.51 (0.35 to 0.74) | 1109 (4) | ⊕⊕⊕O moderate2 | ||
139 per 1000 | 71 per 1000 (49 to 103) | |||||
Low risk population | ||||||
40 per 1000 | 20 per 1000 (14 to 30) | |||||
High risk population | ||||||
160 per 1000 | 82 per 1000 (56 to 118) | |||||
Major bleeding (follow-up: 3–6 months) | Low risk population | RR 1.05 (0.53 to 2.1) | 1120 (4) | ⊕⊕OO low2,3 | ||
30 per 1000 | 31 per 1000 (16 to 63) | |||||
High risk population | ||||||
160 per 1000 | 168 per 1000 (85 to 336) | |||||
Minor bleeding (follow-up: 3–6 months) | Low risk population | RR 0.85 (0.53 to 1.35) | 1120 (4) | ⊕OOO very low2,4 | ||
120 per 1000 | 102 per 1000 (64 to 162) | |||||
High risk population | ||||||
500 per 1000 | 425 per 1000 (265 to 675) | |||||